Shire Seizes On Gaucher Opening With EMEA Filing For Velaglucerase
This article was originally published in The Pink Sheet Daily
Executive Summary
Given the shortage of Genzyme's Cerezyme treatment, European regulators decided to grant an accelerated review for Shire's medication.
You may also be interested in...
Genzyme, FDA Warn Of Foreign Particles Found In Some Lots Of Five Drugs
Although the drugs in question all are manufactured or finished and filled at the Allston Landing, Mass., plant, Genzyme says the current difficulty is not related to prior manufacturing problems associated with that facility.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.